Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05309291
Other study ID # BXU561424
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 29, 2022
Est. completion date September 30, 2023

Study information

Verified date April 2023
Source Baxter Healthcare Corporation
Contact Baxter Clinical Trials Disclosure Call Center
Phone (224) 948-7359
Email Global_CORP_ClinicalTrialsDisclosure@baxter.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Traditional HD therapy is very effective in clearing urea and smaller middle molecules, but is limited in clearing larger middle molecules. These accumulated large middle-molecular-weight uremic toxins may cause and aggravate inflammation, atherosclerosis and calcification, which indirectly lead to the death of patients. Studies have shown that, compared to conventional high-flux HD (HF-HD), HDF that combines diffusion and convection can reduce the all-cause mortality. Compared to the conventional HF-HD, HDF can more effectively clear larger molecular toxins in one session, which may be related to the better clearance effect of HDF on middle-molecular-weight toxins Theranova's innovative Medium Cut-Off® membranes has high permeability and selectivity to uremic toxins (clearance of a molecular weight of up to 45 kDa) and can retain essential proteins, to maintain patient's albumin level during the HD treatment[9]. Its unique membrane and high cut-off characteristics expand the clearance range beyond those of flux membrane dialyzers. Theranova 400 can be widely used in most blood purification centers under conventional HD equipment and treatment modes, with the effect similar to HDF This study is to demonstrate non-inferiority of the Theranova 400 Dialyzer in hemodialysis (HD) mode (hereinafter referred to as Theranova 400) compared to hemodiafiltration (HDF), using FX 800 in HDF mode (hereinafter referred to as FX 800).


Recruitment information / eligibility

Status Recruiting
Enrollment 272
Est. completion date September 30, 2023
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Patients aged =18 years old and =80 years old, regardless of gender; 2. Patients who are able to sign informed consent form (ICF) after an explanation of the proposed study; 3. Patients who receive in-center HD treatment at a site that routinely implements high flux dialysis and HDF; 4. Patients who have been stable receiving in-center HD/HDF for >3 months prior to study enrollment; 5. Patients with kidney failure receiving maintained HD treatment with a history of thrice weekly HD, and at least 1 HDF session within 1 month prior to the study shall be judged by the investigator; 6. Patients who have an adequate arteriovenous (AV) fistula or graft, or dual-lumen tunneled catheter capable of providing a blood flow rate (QB) of at least 250 mL/min; 7. Patients have no changes in dialysis prescription (dialyzer, time, dialysis fluid flow rate (QD), QB, sufficient dialysis anticoagulation, and stable prescribed doses) over last 6 treatments as judged by the investigator. The dialysis treatment time should be 3.5 to 4.5 hours per session with minimum QB of 250 mL/min and QD of 500 mL/min; 8. Patients with a minimum total convective volume (including ultrafiltration (UF)) of 16 L post-dilution for the most recent HDF treatment; 9. Patients who have Kt/Vurea > 1.2 for the last 2 measurements, with the most recent Kt/Vurea measurement taken within 4 weeks before or during study screening. Exclusion Criteria: 1. Patients who have acute kidney injury with the chance for recovery; 2. Pregnant and lactating women; 3. Patients diagnosed with a New York Heart Association (NYHA) Class IV congestive heart failure, or acute coronary syndrome, and/or who have suffered a myocardial infarction within 3 months prior to the start of the study; 4. Patients with known hemodynamic instability, anemia (hemoglobin <90 g/L), and/or patients with hemoglobin >130g/L for coagulation risk; 5. Patients with active or ongoing infection as per investigator's judgement (e.g C-reactive protein [CRP] level more than 5 folds of normal); 6. Patients who are severely malnourished or with significant disease that interferes with liver synthetic function ( e.g. with serum albumin <30 g/L); 7. Patients with positive serology tests for Hepatitis B surface antigen, Hepatitis C total antibody, and advanced liver, or pulmonary disease as judged by the investigator; 8. Patients with positive serology tests for human immunodeficiency virus (HIV), Syphilis; 9. Patients receiving immunosuppressive treatment or with autoimmune disease; 10. Patients with a history of solid tumors requiring anti-cancer therapy in the past or next 6 months, or with a life expectancy of <1 year, or patients with history of hematology neoplasm; 11. Patients who are pre-scheduled for a living donor kidney transplant within the next 1 year, who plan a change to peritoneal dialysis (PD) within the next 1 year, or who require single-needle dialysis therapy; 12. Patients who have had an allergic response to polyarylethersulfone (PAES) or polysulfone (PS) membrane or have history of poor tolerance to dialyzers with synthetic membranes; 13. Patients with a history of severe mental disorders who are unable to provide consent or comply with study procedures as assessed by the investigator; 14. Patients who are currently participating in or have previously participated in other interventional clinical studies during the past 30 days; 15. Patients with any comorbidity possibly conflicting with the study as judged by the investigator.

Study Design


Intervention

Device:
Theranova 400 Dialyzer
Dialysis performed in HD mode.
FX 800 Dialyzer
Dialysis performed in HDF mode.

Locations

Country Name City State
China Baxter Investigational Site Beijing
China Baxter Investigational Site Beijing
China Baxter Investigational Site Dalian
China Baxter Investigational Site Dalian
China Baxter Investigational Site Hangzhou
China Baxter Investigational Site Nanjing
China Baxter Investigational Site Shanghai
China Baxter Investigational Site Shanghai
China Baxter Investigational Site Shenzhen
China Baxter Investigational Site Suzhou

Sponsors (1)

Lead Sponsor Collaborator
Baxter Healthcare Corporation

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction ratio of lambda free light chains (? FLC) One mid-week treatment day dialysis session, pre-dialysis and post-dialysis Up to 1 week
Primary Reduction ratio of beta-2 microglobulin (ß2-MG) One mid-week treatment day dialysis session, pre-dialysis and post-dialysis Up to 1 week
Secondary Assessment of Kt/V urea One mid-week treatment day dialysis session, pre-dialysis and post-dialysis Up to 1 week
Secondary Urea Reduction Ratio (URR) One mid-week treatment day dialysis session, pre-dialysis and post-dialysis Up to 1 week
Secondary Reduction ratio of a1 microglobulin (a1-MG) One mid-week treatment day dialysis session, pre-dialysis and post-dialysis Up to 1 week
Secondary Reduction ratio of Chitinase-3-like protein (YKL-40) One mid-week treatment day dialysis session, pre-dialysis and post-dialysis Up to 1 week
Secondary Reduction ratio of complement factor D (CFD) One mid-week treatment day dialysis session, pre-dialysis and post-dialysis Up to 1 week
Secondary Reduction ratio of myoglobin One mid-week treatment day dialysis session, pre-dialysis and post-dialysis Up to 1 week
Secondary Reduction ratio of kappa free light chains (? FLC) One mid-week treatment day dialysis session, pre-dialysis and post-dialysis Up to 1 week
See also
  Status Clinical Trial Phase
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT00806130 - Health Related Quality of Life and Cognitive Function Among Norwegian Dialysis Patients
Completed NCT00781690 - Reduction of Heparin Dose in Dialysis With Evodial System N/A
Completed NCT00153621 - Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients N/A
Completed NCT06165211 - Nature-Based Sound Application For Hemodialysis Patients N/A
Not yet recruiting NCT04013620 - CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction Phase 3
Withdrawn NCT03998917 - Pathophysiological Characterization of the Neuromuscular Function of a Population With Multiple Comorbidities Suffering From Chronic Renal Failure in Pre-dialysis.
Completed NCT02586376 - Effects of the Low-level Laser Therapy (LLLT) on Muscle Strength (MS) of the Patients With Kidneys Failure (KF) N/A
Completed NCT00794326 - Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD Phase 3
Completed NCT05185999 - Icodextrin Study to Test Short-Term Safety, Tolerability and Preliminary Efficacy of Sodium-Free Solution in PD Patients Phase 1
Completed NCT03076528 - An Innovative Virtually Supervised Exercise for Dialysis Patients Phase 2
Completed NCT02513303 - Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Phase 3
Unknown status NCT00788905 - Comparison of Conventional Dialysis and the Allient System N/A
Completed NCT00804453 - Evaluation of the Biocompatibility of Cartridge Blood Set Versus Standard Blood Line N/A
Completed NCT01085552 - Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects Phase 1
Completed NCT00694824 - Vascular Calcification's Risk Factors in Haemodialysis Patients
Completed NCT00074620 - A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis Phase 2
Withdrawn NCT06030050 - Animal Assisted Intervention for Hemodialysis Outpatients N/A
Recruiting NCT05562869 - Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction Phase 3
Completed NCT03437538 - Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter N/A